Nanotherapeutics Hub joins iiCON to help strengthen UK’s infectious disease products pipeline
The Nanotherapeutics Hub will work with iiCON to support companies looking to develop nanotherapetuics to combat infectious diseases and access the nanomedicne market, which is expected to be worth $169 billion USD by 2026.
The Nanotherapeutics Hub will support companies by providing advanced analytical capabilities and expertise on biocompatibility, biodistribution and pharmacokinetics, physical and chemical characterisation, and the development of better models to improve therapeutic delivery to the biological target site whilst ensuring patient safety.
Led by the Liverpool School of Tropical Medicine (LSTM) and backed by UKRI’s Strength in Places Fund (SIPF), iiCON is aiming to strengthen the UK’s infectious diseases product pipeline. The consortium supports industry in bringing new game-changing therapeutics and products to market in response to the growing global threat of infectious diseases and antimicrobial resistance (AMR).
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.